viralytics in the media, page-17

Viralytics shares soar

Our cancer cure hopeful Viralytics (VLA) saw its shares soar from a low last week of 25c to close at 33c on a turnover of 1.5 million. o far this week they traded as high as 40c.

The move reflects further progress in the clinical trials of its patented CAVATAK injections of melanoma sufferers involving the use of the Coxsackievirus (related to the common cold) to destroy cancer cells.

Under the watchful eye of the US Food and Drug Administration, another four prestigious cancer centres have been recruited to expand the company’s Phase 11 trials on up to 63 target subjects.

Thirteen have now been dosed progressively, with two so far moving on the extension trials. Viralytic’s chief science officer Prof Darren Shafren, of the University of Newcastle, said the Phase 11 trial will be achieved when immune-related, progression-free survival at six months is observed in 12-14 of 63 target subjects.

http://www.eurekareport.com.au/article/2012/10/24/mining-stocks/speculator